Belzutifan With Von Hippel-Lindau (VHL)
Scottsdale/Phoenix, AZ; Rochester, MN
The purpose of this study is to characterize the effectiveness of belzutifan for patients with VHL disease-associated RCC and/or CNS hemangioblastoma treated in real-world clinical practice. The primary effectiveness parameter includes tumor reductive procedures given the clinical importance of this parameter and association with subsequent morbidity and mortality of disease.